Compare EOLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EOLS | REPL |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.4M | 407.1M |
| IPO Year | 2018 | 2018 |
| Metric | EOLS | REPL |
|---|---|---|
| Price | $5.71 | $10.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $15.50 | $5.67 |
| AVG Volume (30 Days) | 776.9K | ★ 3.2M |
| Earning Date | 05-04-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $297,176,000.00 | N/A |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $17.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $3.86 | $1.50 |
| 52 Week High | $10.20 | $13.24 |
| Indicator | EOLS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 53.16 |
| Support Level | $4.02 | $9.69 |
| Resistance Level | $7.16 | $10.71 |
| Average True Range (ATR) | 0.33 | 0.77 |
| MACD | -0.17 | -0.35 |
| Stochastic Oscillator | 11.95 | 36.77 |
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.